<DOC>
	<DOCNO>NCT00224640</DOCNO>
	<brief_summary>Friedreich ataxia , autosomal recessive condition , ascribe frataxin gene expansion , show result iron- induced injury mitochondrial respiratory chain . Buffering free radical short-chain quinone ( Idebenone ) protect patient cardiomyopathy CNS involvement . Removing CNS iron limit impact neurological symptom disease .</brief_summary>
	<brief_title>Iron-Chelating Therapy Friedreich Ataxia</brief_title>
	<detailed_description>The current clinical trial monocentric open phase1-2 trial context rare diseases framework , aim goal define tolerance/efficacy treatment . Inclusion criterion : minimum age : 13 year Follow Dept Genetics , Hospital Necker-Enfants Malades , Paris , France</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Iron Chelating Agents</mesh_term>
	<criteria>1 . Minimum age : 13 year 2 . Molecular confirmation frataxin gene mutation 3 . Iron overload evaluation 4 . Presence lactate 5 . Echography response Idebenone treatment 6 . Urinary test pregnancy girl 7 . Sexual abstinence men 8 . Information consent 1 . No disturbance iron metabolism 2 . No response Idebenone 3 . Friedreich confirm 4 . Polynuclear neutrophils &lt; 2 x 109/L hemoglobin &lt; 8g/dL 5 . No participation trial 6 . Doubt regard compliance patient protocol 7 . Impossibility undergo Xray examination presence iron material backbone 8 . Pregnant woman 9 . Absence social insurance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Iron-chelating treatment</keyword>
</DOC>